巨头哄抢GLP-1资产,利好中国Biotech?

药闻社
Nov 01, 2025

点击上面“蓝字”关注我们!本文来源于医药投资部落;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!跨国巨头辉瑞对Metsera的73亿美元收购案,面临着被诺和诺德“截胡”的风险。10月30日,诺和诺德对外界确认,其主动提交了以90亿美元收购Metsera的提案,这个报价比辉瑞高了17亿美元。这两家公司,一个到目前为止基本错过了GLP-1赛道的盛宴,另一个在主打产品司美格鲁肽显露出增长乏力的趋势后...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10